Normal outcome of pregnancy with ongoing treatment with natalizumab
Article first published online: 15 FEB 2014
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Acta Neurologica Scandinavica
Volume 129, Issue 6, pages e27–e29, June 2014
How to Cite
Normal outcome of pregnancy with ongoing treatment with natalizumab. Acta Neurol Scand 2014: 129: e27–e29. © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd., .
- Issue published online: 8 APR 2014
- Article first published online: 15 FEB 2014
- Manuscript Accepted: 8 JAN 2014
- multiple sclerosis;
Treatment of multiple sclerosis (MS) with natalizumab during pregnancy is not recommended due to potential risks for the foetus. Despite strong advice accidental pregnancies occur.
A 32-year old woman with MS since the age of 26 was treated with natalizumab since January 2008. Treatment was stopped April 2011 due to pregnancy plans, but was restarted following an MS relapse. The patient was thoroughly informed about potential foetal risks, but nevertheless she one year later disclosed that she was pregnant in gestational week 15. Treatment was continued, since the first trimester had passed. The pregnancy course was normal and a healthy daughter was born at full gestational term.
This is the second known case where natalizumab treatment continued throughout the whole gestational period.